The Division of Well being and Human Providers has positioned Johnson & Johnson in command of a Baltimore manufacturing facility the place an ingredient mix-up between vaccines of that firm and people of AstraZeneca ruined 15 million doses, the New York Occasions reported on Saturday. The manufacturing facility, which is managed by Emergent BioSolutions, will solely make vaccines designed by Johnson & Johnson and can stop manufacturing of AstraZeneca photographs. Staff on the manufacturing facility reportedly blended up elements from the vaccines a number of weeks in the past. The Meals and Drug Administration, nevertheless, has not but approved using vaccines made on the facility, that means that not one of the botched doses had been administered within the U.S. Johnson & Johnson is “assuming full duty relating to the manufacturing of drug substance” on the manufacturing facility, the corporate mentioned in an announcement. Moreover, Johnson & Johnson “is including devoted leaders for operations and high quality, and considerably rising the variety of manufacturing, high quality and technical operations personnel to work with the corporate specialists already at Emergent.” AstraZeneca mentioned in an announcement that it “will work with the U.S .Authorities to establish another location for home [vaccine] manufacturing.” The FDA gave emergency authorization to Johnson & Johnson’s vaccine in late February. AstraZeneca’s vaccine has not but obtained emergency authorization. The U.S. authorities paid Emergent BioSolutions $628 million to order manufacturing house at its Baltimore facility in June 2020, as a part of the Trump administration’s Operation Warp Pace. Previously, the FDA would normally enable manufacturing of just one vaccine at a given manufacturing facility to keep away from mix-ups between supplies, consultants on vaccine manufacturing informed the Occasions.